应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09606 映恩生物-B
未开盘 07-18 16:08:33
336.000
+7.600
+2.31%
最高
340.000
最低
321.800
成交量
16.20万
今开
328.400
昨收
328.400
日振幅
5.54%
总市值
295.80亿
流通市值
295.80亿
总股本
8,804万
成交额
5,416万
换手率
0.18%
流通股本
8,804万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
映恩生物-B07月17日主力净流入777.4万元 散户资金抛售
市场透视 · 07-17
映恩生物-B07月17日主力净流入777.4万元 散户资金抛售
港股创新药概念股持续上攻,康方生物等多股创历史新高
老虎资讯综合 · 07-17
港股创新药概念股持续上攻,康方生物等多股创历史新高
映恩生物-B股价刷上市新高,该股上市以来累涨225%
老虎资讯综合 · 07-16
映恩生物-B股价刷上市新高,该股上市以来累涨225%
映恩生物-B07月15日获主力加仓48.4万元
市场透视 · 07-15
映恩生物-B07月15日获主力加仓48.4万元
映恩生物-B07月14日主力净流入70.7万元 散户资金抛售
市场透视 · 07-14
映恩生物-B07月14日主力净流入70.7万元 散户资金抛售
映恩生物-B07月09日主力净流入894.9万元 散户资金抛售
市场透视 · 07-09
映恩生物-B07月09日主力净流入894.9万元 散户资金抛售
映恩生物-B07月03日主力净流入202.6万元 散户资金抛售
市场透视 · 07-03
映恩生物-B07月03日主力净流入202.6万元 散户资金抛售
【券商聚焦】华泰证券:19只个股9月或将被纳入港股通范围
金吾财讯 · 07-02
【券商聚焦】华泰证券:19只个股9月或将被纳入港股通范围
映恩生物-B06月25日遭主力抛售395.5万元
市场透视 · 06-25
映恩生物-B06月25日遭主力抛售395.5万元
映恩生物-B06月16日主力净流出167.7万元 散户资金买入
市场透视 · 06-16
映恩生物-B06月16日主力净流出167.7万元 散户资金买入
医药生物IPO“港漂”热潮:三大热门创新药成焦点,恒瑞医药4个月便实现A+H
时代周报 · 06-13
医药生物IPO“港漂”热潮:三大热门创新药成焦点,恒瑞医药4个月便实现A+H
一周港股牛熊榜 | 生物医药股涨势如虹,绿叶制药全周涨超33%居榜首,晶泰控股涨超28%;半导体股上海复旦承压,全周跌9.45%
老虎資訊 · 06-13
一周港股牛熊榜 | 生物医药股涨势如虹,绿叶制药全周涨超33%居榜首,晶泰控股涨超28%;半导体股上海复旦承压,全周跌9.45%
24家药企股价翻倍
医药研究社 · 06-11
24家药企股价翻倍
映恩生物-B06月11日主力净流出240.3万元 散户资金买入
市场透视 · 06-11
映恩生物-B06月11日主力净流出240.3万元 散户资金买入
港股异动 | 生物医药板块多日走强,映恩生物再涨14%,三生制药涨超10%
老虎资讯综合 · 06-10
港股异动 | 生物医药板块多日走强,映恩生物再涨14%,三生制药涨超10%
港股异动 | 次新股午后涨势不止,布鲁可涨幅扩大至24%,健康之路涨近15%,映恩生物涨超11%
老虎资讯综合 · 06-09
港股异动 | 次新股午后涨势不止,布鲁可涨幅扩大至24%,健康之路涨近15%,映恩生物涨超11%
映恩生物-B盘中涨超13%创上市新高 公司自研ADC管线丰富
新浪港股 · 06-09
映恩生物-B盘中涨超13%创上市新高 公司自研ADC管线丰富
格隆汇个股放量排行榜 | 6月8日
格隆汇 · 06-08
格隆汇个股放量排行榜 | 6月8日
【券商聚焦】招银国际首予映恩生物(09606)买入评级 指其拥有丰富的自研ADC管线
金吾财讯 · 06-06
【券商聚焦】招银国际首予映恩生物(09606)买入评级 指其拥有丰富的自研ADC管线
映恩生物-BEmerging as a global leader in ADC in
招银国际 · 06-06
映恩生物-BEmerging as a global leader in ADC in
加载更多
公司概况
公司名称:
映恩生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物(ADC)创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌(EC)、乳腺癌(BC)、小细胞肺癌(SCLC)、去势抵抗性前列腺癌(CRPC)、食管鳞状细胞癌(ESCC)及头颈部鳞状细胞癌(HNSCC)。该公司主要在国内和国外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":336,"timestamp":1752826113848,"preClose":328.4,"halted":0,"volume":162000,"delay":0,"floatShares":88036299,"shares":88036299,"eps":-143.53665817068767,"marketStatus":"未开盘","change":7.6,"latestTime":"07-18 16:08:33","open":328.4,"high":340,"low":321.8,"amount":54160112,"amplitude":0.05542,"askPrice":336,"askSize":2200,"bidPrice":335,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-143.53666910229646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753061400000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":328.4,"openAndCloseTimeList":[[1752802200000,1752811200000],[1752814800000,1752825600000]],"volumeRatio":0.7227316043789919,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2552543546","title":"映恩生物-B07月17日主力净流入777.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2552543546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552543546?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:15","pubTimestamp":1752740124,"startTime":"0","endTime":"0","summary":"07月17日, 映恩生物-B股价涨5.73%,报收328.40元,成交金额1.6亿元,换手率0.54%,振幅8.31%,量比2.44。映恩生物-B今日主力资金净流入777.4万元,上一交易日主力净流出291.8万元。该股近5个交易日上涨14.73%,主力资金累计净流入604.6万元;近20日主力资金累计净流出341.7万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717170946a6af67c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717170946a6af67c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"1126684543","title":"港股创新药概念股持续上攻,康方生物等多股创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1126684543","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126684543?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:39","pubTimestamp":1752716365,"startTime":"0","endTime":"0","summary":"7月17日,港股创新药概念股延续强势,$康方生物(09926)$涨超8%,$三生制药(01530)$、$乐普生物-B(02157)$涨超6%,$亚盛医药-B(06855)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","BK1583","BK1161","LU0348784397.USD","IE00B543WZ88.USD","LU2488822045.USD","09606","BK1593","BK1574","LU1720050803.USD","01530","09926","LU0348783233.USD","BK4614","LU1794554557.SGD","IE00BPRC5H50.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"1178832126","title":"映恩生物-B股价刷上市新高,该股上市以来累涨225%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178832126","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178832126?lang=zh_cn&edition=full","pubTime":"2025-07-16 10:27","pubTimestamp":1752632860,"startTime":"0","endTime":"0","summary":"7月16日,$映恩生物-B(09606)$再涨3%!高见309.6港元刷上市新高,该股上市以来累涨225%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2551508241","title":"映恩生物-B07月15日获主力加仓48.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551508241","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551508241?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:16","pubTimestamp":1752567368,"startTime":"0","endTime":"0","summary":"07月15日, 映恩生物-B股价涨4.02%,报收300.20元,成交金额3978.2万元,换手率0.15%,振幅6.72%,量比0.57。映恩生物-B今日主力资金净流入48.4万元,上一交易日主力净流入70.7万元。该股近5个交易日上涨6.08%,主力资金累计净流入862.4万元;近20日主力资金累计净流入693.6万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715170220a6aabc35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715170220a6aabc35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2551147901","title":"映恩生物-B07月14日主力净流入70.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2551147901","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551147901?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:15","pubTimestamp":1752480959,"startTime":"0","endTime":"0","summary":"07月14日, 映恩生物-B股价涨0.28%,报收288.60元,成交金额4434.4万元,换手率0.18%,振幅4.79%,量比0.67。映恩生物-B今日主力资金净流入70.7万元,上一交易日主力净流出0万元。该股近5个交易日上涨4.95%,主力资金累计净流入814.0万元;近20日主力资金累计净流入477.4万元,其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714171035a4498089&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714171035a4498089&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2550268733","title":"映恩生物-B07月09日主力净流入894.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550268733","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550268733?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:15","pubTimestamp":1752048927,"startTime":"0","endTime":"0","summary":"07月09日, 映恩生物-B股价涨6.22%,报收300.60元,成交金额1.1亿元,换手率0.44%,振幅7.07%,量比1.51。映恩生物-B今日主力资金净流入894.9万元,上一交易日主力净流出0万元。该股近5个交易日上涨26.30%,主力资金累计净流入837.7万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入639.2万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709165400a43ff0cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709165400a43ff0cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2548443800","title":"映恩生物-B07月03日主力净流入202.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548443800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548443800?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:15","pubTimestamp":1751530533,"startTime":"0","endTime":"0","summary":"07月03日, 映恩生物-B股价涨9.24%,报收260.00元,成交金额7866.2万元,换手率0.35%,振幅12.18%,量比1.29。映恩生物-B今日主力资金净流入202.6万元,上一交易日主力净流出221.3万元。该股近5个交易日上涨5.52%,主力资金累计净流出627.7万元;近20日主力资金累计净流入1466.1万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703170143a4ccfae4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703170143a4ccfae4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2548852360","title":"【券商聚焦】华泰证券:19只个股9月或将被纳入港股通范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2548852360","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548852360?lang=zh_cn&edition=full","pubTime":"2025-07-02 13:49","pubTimestamp":1751435347,"startTime":"0","endTime":"0","summary":"因此,海天味业、三花智控对应港股入通时间更早,将分别于7月17日、7月21日纳入港股通。南向资金在香港市场的重要性的持续提升,或进一步放大本轮港股通标的调整带来的流动性效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702135508a729dd3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702135508a729dd3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","01729","09678","BK1116","BK1564","HSCEI","07226","HSTECH","06886","02609","BK1147","02610"],"gpt_icon":0},{"id":"2546213941","title":"映恩生物-B06月25日遭主力抛售395.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546213941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546213941?lang=zh_cn&edition=full","pubTime":"2025-06-25 16:15","pubTimestamp":1750839322,"startTime":"0","endTime":"0","summary":"06月25日, 映恩生物-B股价跌2.99%,报收246.20元,成交金额5169.9万元,换手率0.24%,振幅4.96%,量比1.10。映恩生物-B今日主力资金净流出395.5万元,连续3日净流出,上一交易日主力净流出218.4万元。该股近5个交易日下跌4.22%,主力资金累计净流出802.2万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入2609.0万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625172536a71cc618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625172536a71cc618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2543789476","title":"映恩生物-B06月16日主力净流出167.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2543789476","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543789476?lang=zh_cn&edition=full","pubTime":"2025-06-16 16:15","pubTimestamp":1750061708,"startTime":"0","endTime":"0","summary":"06月16日, 映恩生物-B股价跌4.54%,报收261.00元,成交金额8724.0万元,换手率0.38%,振幅7.10%,量比0.67。映恩生物-B今日主力资金净流出167.7万元,上一交易日主力净流入71.6万元。该股近5个交易日上涨8.75%,主力资金累计净流入1063.1万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入505.8万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616172443a4abbd4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616172443a4abbd4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2543681110","title":"医药生物IPO“港漂”热潮:三大热门创新药成焦点,恒瑞医药4个月便实现A+H","url":"https://stock-news.laohu8.com/highlight/detail?id=2543681110","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543681110?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:50","pubTimestamp":1749815428,"startTime":"0","endTime":"0","summary":"部分企业“弃A转港”,或为这波港股医药生物IPO热潮添一把火。排队IPO企业方面,截至今年5月31日,港股医药生物IPO申报企业共有20家。医药生物企业扎堆赴港IPO,或与A股IPO审核趋严有关。未盈利医药生物企业扎堆赴港IPO,与港交所创新性推出的18A上市规则有关。例如,恒瑞医药、派格生物、觅瑞等均在招股书中明确提出“出海”计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","06978","BK1191","BK1574","02561","BK1161","09606"],"gpt_icon":1},{"id":"1106617128","title":"一周港股牛熊榜 | 生物医药股涨势如虹,绿叶制药全周涨超33%居榜首,晶泰控股涨超28%;半导体股上海复旦承压,全周跌9.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106617128","media":"老虎資訊","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106617128?lang=zh_cn&edition=full","pubTime":"2025-06-13 17:15","pubTimestamp":1749806141,"startTime":"0","endTime":"0","summary":"生物医药股本周涨势亮眼, $绿叶制药$本周升33.33%居榜首, $晶泰控股$ 涨超28%。完善基本医疗保险药品目录调整机制,制定出台商业健康保险创新药品目录,更好满足人民群众多层次用药保障需求。5月下旬,中国创新药企再次闪耀ASCO,共有71项原创性研究成果入选口头发言环节。最常见不良事件为胃肠道和血液学毒性,临床管理良好。$上海复旦$ 本周跌9.45%,消息面上,中芯国际、华虹半导体此前发布的二季度指引谨慎。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/6b12b30d7cf0af9a2b6d2683230cd48c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/6b12b30d7cf0af9a2b6d2683230cd48c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","02570","HSI","01385","HSTECH","00467","02865","02186","02858","HSCEI","02228"],"gpt_icon":1},{"id":"2542584991","title":"24家药企股价翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2542584991","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542584991?lang=zh_cn&edition=full","pubTime":"2025-06-11 20:21","pubTimestamp":1749644478,"startTime":"0","endTime":"0","summary":"截至6月3日,今年A股和H股医药板块上涨明显,约70%企业股价上涨,多家药企股价实现翻倍增长。据药智网统计和铂医药、舒泰神、加科思、荣昌生物、三生制药、一品红等24家公司股价在今年实现翻倍式上涨。其中德琪医药股价上涨5倍多,成为今年医药行业的“涨幅冠军”。多数创新药企业仍处于未盈利状态,未来管线的进展将大幅影响其股价的涨跌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611202857a4a383f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611202857a4a383f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","02171","02142","688336","09995","688331","01167","09606","688382","BK0239","01672","06622","688068","01530"],"gpt_icon":1},{"id":"2542302057","title":"映恩生物-B06月11日主力净流出240.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2542302057","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542302057?lang=zh_cn&edition=full","pubTime":"2025-06-11 16:15","pubTimestamp":1749629723,"startTime":"0","endTime":"0","summary":"06月11日, 映恩生物-B股价跌0.74%,报收269.40元,成交金额9129.7万元,换手率0.39%,振幅6.19%,量比0.65。映恩生物-B今日主力资金净流出240.3万元,上一交易日主力净流入1150.0万元。该股近5个交易日上涨24.20%,主力资金累计净流入1221.8万元;近20日主力资金累计净流入487.7万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611173057a4a3483d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611173057a4a3483d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"1185274559","title":"港股异动 | 生物医药板块多日走强,映恩生物再涨14%,三生制药涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185274559","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185274559?lang=zh_cn&edition=full","pubTime":"2025-06-10 10:53","pubTimestamp":1749524029,"startTime":"0","endTime":"0","summary":"本周二港股早盘,生物医药板块持续走强, $映恩生物-B$ 再涨14%,两日累涨近30%, $三生制药$ 涨超10%, $康方生物$ 涨近5%:消息面上,生物医药板块正经历“创新成果兑现+全球化突破”的双重红利期。华鑫证券指出,国内创新药进入“研发投入-销售放量-回报反哺”的正循环,根据医药魔方数据,2025年Q1中国医药交易金额同比激增222%,三生制药、石药集团等Pharma类企业凭借稳定现金流支撑管线升级。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","06160","03759","02359","02696","06622","06606","06618","01530","06996","01801","03347","02269","09606","09995","00241"],"gpt_icon":0},{"id":"1189305925","title":"港股异动 | 次新股午后涨势不止,布鲁可涨幅扩大至24%,健康之路涨近15%,映恩生物涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189305925","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189305925?lang=zh_cn&edition=full","pubTime":"2025-06-09 13:32","pubTimestamp":1749447161,"startTime":"0","endTime":"0","summary":"本周一,港股次新股午后涨势不止,$布鲁可(00325)$涨幅扩大至24%,$健康之路(02587)$涨近15%、 $映恩生物-B(09606)$ 涨超11%,三家均创历史新高!入通的$蜜雪集团(02097)$和 $古茗(01364)$ 均涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a7ed81b1e72df2f2f0f21497fe08eaed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a7ed81b1e72df2f2f0f21497fe08eaed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","LU0211977185.USD","07226","09606","BK1219","BK1213","HSCEI","00325","BK4614","02587"],"gpt_icon":0},{"id":"2542879848","title":"映恩生物-B盘中涨超13%创上市新高 公司自研ADC管线丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2542879848","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542879848?lang=zh_cn&edition=full","pubTime":"2025-06-09 11:14","pubTimestamp":1749438840,"startTime":"0","endTime":"0","summary":" 映恩生物-B早盘一度涨超13%,盘中高见243.2港元,创上市新高。截至发稿,股价上涨11.66%,报239.40港元,成交额8327.82万港元。 该行指出,映恩生物秉持全球化战略,已建立多项战略合作,加速其产品线在全球关键市场的开发。映恩生物致力于成为全球生物医药公司在ADC领域的首选合作伙伴,其一系列高质量合作不仅验证了公司平台和产品线的价值,也体现了其合作模式的高度可复制性,为未来持续的创新和增长奠定坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-06-09/doc-inezmvxn4623714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK4231","ADC","09606","BK4080"],"gpt_icon":0},{"id":"2541510840","title":"格隆汇个股放量排行榜 | 6月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=2541510840","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541510840?lang=zh_cn&edition=full","pubTime":"2025-06-08 17:30","pubTimestamp":1749375003,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示,上一交易日宏利金融-S(00945)、香港华人有限公司(00655)、联合能源集团(00467)、中国高精密(00591)、智城发展控股(08268)、移卡(09923)、完美医疗(01830)、百利保控股(00617)、裕元集团(00551)、中华银科技(00515)、阳光油砂(02012)、海丰国际(01308)、味千(中国)(00538)、兖矿能源(01171)、MET","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/08173050935774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00382","00169","02160","02878","01606","00467","00655","02230","00517","00011","00384","00290","01030","02128","09606","01883","00165","02559","00215","00012","00669","02669","00754","03383","00398","02666","01468","00003","00520","01499","01052","01440","00340","00799","02256","00440","00617","02196","00370","00998","00788","02216","09959","00538","00551","02668","00631","02696"],"gpt_icon":1},{"id":"2541229882","title":"【券商聚焦】招银国际首予映恩生物(09606)买入评级 指其拥有丰富的自研ADC管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2541229882","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541229882?lang=zh_cn&edition=full","pubTime":"2025-06-06 13:14","pubTimestamp":1749186864,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指,映恩生物 拥有丰富的自研ADC管线:DB-1303/BNT323的首个适应症为HER2表达的子宫内膜癌,管理层预计最快将今年向FDA申请加速上市申请;DB-1311/BNT324正在开发单药及联合治疗用于小细胞肺癌;DB-1310采用差异化的开发策略,聚焦于与奥希替尼联合用于EGFR突变NSCLC及KRAS突变NSCLC患者;DB-1305/BNT325聚焦于其他TROP2 ADC尚未深入布局的适应症领域,如卵巢癌。首次覆盖,给予买入评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960005","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","ADC"],"gpt_icon":0},{"id":"2541288507","title":"映恩生物-BEmerging as a global leader in ADC in","url":"https://stock-news.laohu8.com/highlight/detail?id=2541288507","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541288507?lang=zh_cn&edition=full","pubTime":"2025-06-06 10:16","pubTimestamp":1749176164,"startTime":"0","endTime":"0","summary":"公司凭借其差异化的ADC产品管线和战略合作伙伴关系,迅速成为行业内的焦点。根据报告,DualityBio的核心优势在于其自主研发的ADC技术平台以及广泛的全球合作网络,目前已有超过60亿美元的合作交易价值。公司已与BioNTech、BeiGene、GSK等国际制药巨头达成合作,涵盖多个ADC项目和技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606102840a49c3c63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606102840a49c3c63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":0.1675},{"period":"1month","weight":0.3135},{"period":"3month","weight":0.68},{"period":"6month","weight":2.5518},{"period":"ytd","weight":2.5518}],"compareEarnings":[{"period":"1week","weight":0.0284},{"period":"1month","weight":0.047},{"period":"3month","weight":0.1603},{"period":"6month","weight":0.2676},{"period":"1year","weight":0.3964},{"period":"ytd","weight":0.2376}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物(ADC)创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌(EC)、乳腺癌(BC)、小细胞肺癌(SCLC)、去势抵抗性前列腺癌(CRPC)、食管鳞状细胞癌(ESCC)及头颈部鳞状细胞癌(HNSCC)。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}